Blueprint Medicines
Blueprint Medicines Inks $1.25B Financing Deal in Exchange for Royalties of Ayvakit, Gavreto
Sixth Street is providing funds in exchange for future royalties of Ayvakit and the KIT D816V inhibitor BLU-263, while Royalty Pharma inked a similar deal for Gavreto.